CD19 and acute lymphoblastic leukemia: Furthermore, it is noteworthy that, in 2014, in treating ALL, the utilisation of tyrosine kinase inhibitors for Philadelphia chromosome-positive ALL and bispecific T-cell engager (CD19/CD3) monoclonal antibody therapy led to decreased ASDR.